BMS combo available to UK patients with cancer generally caused by asbestos

14 July 2022

The UK's National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM), in England and Wales.

This combination from US pharma major Bristol Myers Squibb (NYSE: BMY) is the first immunotherapy in more than 10 years to be made available via the National Health Service (NHS) for the treatment of untreated, unresectable MPM.

"Not only do MPM patients have an alternative treatment option, but one that has demonstrated positive overall survival in comparison to chemotherapy"Within the FAD, the NICE committee also recommended extending the combination to treat rarer forms of mesothelioma found in the pericardium and peritoneum.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK